Humacyte reports 44% increase in hospitals ordering Symvess to 49 in Q3 2026

Humacyte reported accelerating commercial adoption of Symvess, with a 44% increase in hospitals ordering the product to 49 in Q3 2026, citing rising surgeon use and recent expansion in Florida. The company plans Phase 3 ATEV data later this year.

Detected & updated continuously · Source: Nebula